Cargando…
How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?
The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmi...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer India
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274942/ https://www.ncbi.nlm.nih.gov/pubmed/32837051 http://dx.doi.org/10.1007/s12288-020-01300-0 |
_version_ | 1783542677642412032 |
---|---|
author | Jain, Arihant Singh, Charanpreet Dhawan, Rishi Jindal, Nishant Mohindra, Ritin Lad, Deepesh Prakash, Gaurav Khadwal, Alka Suri, Vikas Bhalla, Ashish Kumari, Savita Varma, Neelam John, M Joseph Mahapatra, Manoranjan Malhotra, Pankaj |
author_facet | Jain, Arihant Singh, Charanpreet Dhawan, Rishi Jindal, Nishant Mohindra, Ritin Lad, Deepesh Prakash, Gaurav Khadwal, Alka Suri, Vikas Bhalla, Ashish Kumari, Savita Varma, Neelam John, M Joseph Mahapatra, Manoranjan Malhotra, Pankaj |
author_sort | Jain, Arihant |
collection | PubMed |
description | The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies. |
format | Online Article Text |
id | pubmed-7274942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer India |
record_format | MEDLINE/PubMed |
spelling | pubmed-72749422020-06-08 How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? Jain, Arihant Singh, Charanpreet Dhawan, Rishi Jindal, Nishant Mohindra, Ritin Lad, Deepesh Prakash, Gaurav Khadwal, Alka Suri, Vikas Bhalla, Ashish Kumari, Savita Varma, Neelam John, M Joseph Mahapatra, Manoranjan Malhotra, Pankaj Indian J Hematol Blood Transfus Review Article The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies. Springer India 2020-06-06 2020-10 /pmc/articles/PMC7274942/ /pubmed/32837051 http://dx.doi.org/10.1007/s12288-020-01300-0 Text en © Indian Society of Hematology and Blood Transfusion 2020 |
spellingShingle | Review Article Jain, Arihant Singh, Charanpreet Dhawan, Rishi Jindal, Nishant Mohindra, Ritin Lad, Deepesh Prakash, Gaurav Khadwal, Alka Suri, Vikas Bhalla, Ashish Kumari, Savita Varma, Neelam John, M Joseph Mahapatra, Manoranjan Malhotra, Pankaj How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? |
title | How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? |
title_full | How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? |
title_fullStr | How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? |
title_full_unstemmed | How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? |
title_short | How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India? |
title_sort | how to use a prioritised approach for treating hematological disorders during the covid-19 pandemic in india? |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7274942/ https://www.ncbi.nlm.nih.gov/pubmed/32837051 http://dx.doi.org/10.1007/s12288-020-01300-0 |
work_keys_str_mv | AT jainarihant howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT singhcharanpreet howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT dhawanrishi howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT jindalnishant howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT mohindraritin howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT laddeepesh howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT prakashgaurav howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT khadwalalka howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT surivikas howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT bhallaashish howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT kumarisavita howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT varmaneelam howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT johnmjoseph howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT mahapatramanoranjan howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia AT malhotrapankaj howtouseaprioritisedapproachfortreatinghematologicaldisordersduringthecovid19pandemicinindia |